Figure 3
Induction of apoptosis markers by lumiliximab in CLL cells. CLL cells from 3 patients were assessed for induction of apoptosis markers by lumiliximab. Cells were incubated in the presence of 10 μg/mL lumiliximab or CE9.1 isotype control antibody, followed by crosslinking with F(ab′)2 goat-antihuman IgG. After 18 hours, cells were harvested and subjected to Western blot analysis with (A) anti–caspase-3, (B) anti-PARP, (C) anticleaved caspase-9, and (D) anticaspase-8 antibodies. A representative sample is shown in panels A-D.
